Zhitong Finance App News, Tongyuankang Pharmaceutical-B (02410.HK) announced that the company is developing a new class 1 drug, edotinib mesylate tablets (TY-9591 tablets), will be included in the list of priority review varieties by the National Drug Administration (NMPA) Drug Evaluation Center (CDE). The proposed indications are: having an epidermal growth factor receptor (EGFR) exon 19 deficiency (19DEL) or exon 21 (L858R) replacement mutation, accompanied by late central nervous system (CNS) metastasis stage or metastatic non-small cell lung cancer (NSCLC) ) First-line treatment for adult patients.

Zhitong Finance App News, Tongyuankang Pharmaceutical-B (02410.HK) announced that the company is developing a new class 1 drug, edotinib mesylate tablets (TY-9591 tablets), will be included in the list of priority review varieties by the National Drug Administration (NMPA) Drug Evaluation Center (CDE). The proposed indications are: having an epidermal growth factor receptor (EGFR) exon 19 deficiency (19DEL) or exon 21 (L858R) replacement mutation, accompanied by late central nervous system (CNS) metastasis stage or metastatic non-small cell lung cancer (NSCLC) ) First-line treatment for adult patients.